Int J Stomatol

Int J Stomatol ›› 2022, Vol. 49 ›› Issue (4): 471-475.doi: 10.7518/gjkq.2022069

• Reviews • Previous Articles     Next Articles

Research progress on Nod-like receptor protein 3 inflammasome in oral mucosal diseases

Chen Siting(),Zhong Xiong,Meng Wenxia.()   

  1. Dept. of Oral Medicine, Stomatological Hospital, Southern Medical University, Guangzhou 510280, China
  • Received:2021-10-02 Revised:2022-02-12 Online:2022-07-01 Published:2022-06-28
  • Contact: Wenxia. Meng E-mail:csiting08@163.com;mengwx2008@foxmail.com
  • Supported by:
    National Natural Science Foundation of China(81500850)

RichHTML

18

PDF (PC)

272

Abstract:

Nod-like receptor protein 3 (NLRP3) inflammasome is a cytoplasmic macromolecular protein complex that recognizes bacteria, viruses, and other pathogens, as well as a variety of danger signals. It plays an important role in the immune system’s resistance to pathogen invasion. NLRP3 inflammasome also induces the release of pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18 by activating caspase-1, thereby causing an inflammatory response. Previous studies confirmed that NLRP3 inflammasome plays an important regulatory role in autoimmune and infectious diseases, such as rheumatoid arthritis and cardiovascular infections. However, the current research on NLRP3 inflammasome in oral mucosal diseases is still in its infancy. Combined with the related research at home and abroad in recent years, this paper briefly summarizes the research progress on the correlation between NLRP3 inflammasome and common oral mucosa diseases (such as oral lichen planus, recurrent aphthous ulcer, and autoimmune bullous diseases) and provides reference for the further study and application of NLRP3 inflammasome in oral mucosal diseases.

Key words: Nod-like receptor protein 3 inflammasome, oral lichen planus, recurrent aphthous ulcer, autoimmune bullous disease, Nod-like receptor protein 3 inflammasome inhibitor

CLC Number: 

  • R 781.5

TrendMD: 
1 He Y, Hara H, Núñez G. Mechanism and regulation of NLRP3 inflammasome activation[J]. Trends Biochem Sci, 2016, 41(12): 1012-1021.
2 Li Z, Guo JL, Bi LQ. Role of the NLRP3 inflammasome in autoimmune diseases[J]. Biomedecine Pharmacother, 2020, 130: 110542.
3 Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to the-rapeutics[J]. Nat Rev Immunol, 2019, 19(8): 477-489.
4 Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines[J]. Immunol Rev, 2008, 223: 20-38.
5 Ghahremanlo A, Boroumand N, Ghazvini K, et al. Herbal medicine in oral lichen planus[J]. Phytother Res, 2019, 33(2): 288-293.
6 Tsushima F, Sakurai J, Uesugi A, et al. Malignant transformation of oral lichen planus: a retrospective study of 565 Japanese patients[J]. BMC Oral Health, 2021, 21(1): 298.
7 Roopashree MR, Gondhalekar RV, Shashikanth MC, et al. Pathogenesis of oral lichen planus: a review[J]. J Oral Pathol Med, 2010, 39(10): 729-734.
8 Thi Do T, Phoomak C, Champattanachai V, et al. New evidence of connections between increased O-GlcNAcylation and inflammasome in the oral mucosa of patients with oral lichen planus[J]. Clin Exp Immunol, 2018, 192(1): 129-137.
9 Lv KJ, Wang GH, Shen CL, et al. Role and mechanism of the nod-like receptor family pyrin domain-containing 3 inflammasome in oral disease[J]. Arch Oral Biol, 2019, 97: 1-11.
10 Slebioda Z, Szponar E, Kowalska A. Etiopathogenesis of recurrent aphthous stomatitis and the role of immunologic aspects: literature review[J]. Arch Immunol Ther Exp (Warsz), 2014, 62(3): 205-215.
11 Natah SS, Konttinen YT, Enattah NS, et al. Recurrent aphthous ulcers today: a review of the growing knowledge[J]. Int J Oral Maxillofac Surg, 2004, 33(3): 221-234.
12 Bidoki AZ, Harsini S, Sadr M, et al. NLRP3 gene polymorphisms in Iranian patients with recurrent aphthous stomatitis[J]. J Oral Pathol Med, 2016, 45(2): 136-140.
13 Slezakova S, Borilova Linhartova P, Masopustova L, et al. Association of the NOD-like receptor 3 (NLRP3) gene variability with recurrent aphthous stomatitis in the Czech population[J]. J Oral Pathol Med, 2018, 47(4): 434-439.
14 Hise AG, Tomalka J, Ganesan S, et al. An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans [J]. Cell Host Microbe, 2009, 5(5): 487-497.
15 Engineer L, Bhol KC, Ahmed AR. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris[J]. J Am Acad Dermatol, 2000, 43(6): 1049-1057.
16 Shamsabadi RM, Basafa S, Yarahmadi R, et al. Elevated expression of NLRP1 and IPAF are related to oral pemphigus vulgaris pathogenesis[J]. Inflammation, 2015, 38(1): 205-208.
17 Fang H, Shao S, Cao TY, et al. Increased expression of NLRP3 inflammasome components and interleukin-18 in patients with bullous pemphigoid[J]. J Dermatol Sci, 2016, 83(2): 116-123.
18 Koga H, Recke A, Vidarsson G, et al. PDE4 inhibition as potential treatment of epidermolysis bullosa acquisita[J]. J Invest Dermatol, 2016, 136(11): 2211-2220.
19 Izumi K, Bieber K, Ludwig RJ. Current clinical trials in pemphigus and pemphigoid[J]. Front Immunol, 2019, 10: 978.
20 Koga H, Kasprick A, López R, et al. Therapeutic effect of a novel phosphatidylinositol-3-kinase δ inhibitor in experimental epidermolysis bullosa acquisita[J]. Front Immunol, 2018, 9: 1558.
21 Liang L, Tan XY, Zhou QY, et al. IL-1β triggered by peptidoglycan and lipopolysaccharide through TLR2/4 and ROS-NLRP3 inflammasome-dependent pathways is involved in ocular Behçet’s disease[J]. Invest Ophthalmol Vis Sci, 2013, 54(1): 402-414.
22 Kim EH, Park MJ, Park S, et al. Increased expression of the NLRP3 inflammasome components in patients with Behçet’s disease[J]. J Inflamm (Lond), 2015, 12: 41.
23 Li L, Yu HS, Jiang YN, et al. Genetic Variations of NLR family genes in Behcet’s disease[J]. Sci Rep, 2016, 6: 20098.
24 Seok JK, Kang HC, Cho YY, et al. Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases[J]. Arch Pharm Res, 2021, 44(1): 16-35.
25 Coll RC, Robertson AA, Chae JJ, et al. A small-mo-lecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases[J]. Nat Med, 2015, 21(3): 248-255.
26 Juliana C, Fernandes-Alnemri T, Wu JH, et al. Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome[J]. J Biol Chem, 2010, 285(13): 9792-9802.
27 Zhao JJ, Wang HY, Dai C, et al. P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/caspase 1 pathway[J]. Arthritis Rheum, 2013, 65(12): 3176-3185.
28 Keane RW, Dietrich WD, de Rivero Vaccari JP. Inflammasome proteins as biomarkers of multiple sclerosis[J]. Front Neurol, 2018, 9: 135.
[1] Li Ran,Hu Yue,Zhang Ning,Gao Ruifang,Wang Xiangyu,Ge Xuejun. The correlation study between single nucleotide polymorphisms of Toll-like receptor and interleukin-17 and oral lichen planus [J]. Int J Stomatol, 2024, 51(1): 45-51.
[2] Wang Sujie,Tan Qin,Wei Yuan,Wang Jie,Fan Jie,Yue Erli.. Correlation analysis of serum angiopoietin-2 level with forkhead/winged helix transcription factor p3 regulatory T cells and disease activity in patients with oral lichen planus [J]. Int J Stomatol, 2023, 50(6): 674-678.
[3] He Jing,Hu Mingjia,Xiao Ning,Li Jia,Sun Wanxin,Ling Lü,Liu Fan. Investigation on the degree of psychological distress and its influencing factors in patients with oral lichen planus [J]. Int J Stomatol, 2023, 50(3): 308-313.
[4] Zhang Shenyi,Wang Xiangjian,Shi Liran,Shi Jiahong,Wang Yuhong,Zhou Hongmei. Oral beta-carotene in the treatment of non-erosive oral lichen planus: a randomized controlled trial [J]. Int J Stomatol, 2022, 49(6): 633-640.
[5] Liu Siyu,Li Xin,Xu Xiaoyu,Sun Yinyin,Pan Yingxiao,Wang Sainan,Lu Shulai. Research advances in the relationship between oral lichen planus and cardiovascular diseases [J]. Int J Stomatol, 2021, 48(2): 141-146.
[6] Feng Lu,Meng Wenxia. Research progress on the problems of dental implant treatment in patients with common oral mucosal disease [J]. Int J Stomatol, 2021, 48(2): 147-155.
[7] Yuan Zhenying,Guan Cuiqiang,Nan Xinrong. Research progress on DNA methylation and oral disease [J]. Int J Stomatol, 2019, 46(4): 437-441.
[8] Shuaihua Qin,Xinming Li,Wenlu Li. Evaluation and correlation analysis of quality of life and coping strategies in patients with symptomatic oral lichen planus [J]. Int J Stomatol, 2019, 46(3): 282-286.
[9] Jing Wang,Yan Wang,Chuandong Wang,Ruijie Huang,Yan Tian,Wei Hu,Jing Zou. Application of liquorice and its extract to the prevention and treatment of oral infections and associated diseases [J]. Inter J Stomatol, 2018, 45(5): 546-552.
[10] Meng Wenxia, Jiang Liyi, Lai Yanqun, Yao Yanmei. Thinking on a case of atypical performance of acquired immure deficiency syndrome [J]. Inter J Stomatol, 2018, 45(2): 132-134.
[11] Cai Donglin, Lu Rui. Research progress on the etiology of recurrent aphthous ulcer in children [J]. Inter J Stomatol, 2018, 45(2): 145-149.
[12] Zhou Yi, Sun Xiurong, Liu Xueli, Yan Shixia. Effect of psychological intervention on the treatment of oral lichen planus [J]. Inter J Stomatol, 2016, 43(1): 22-.
[13] Wang Yuhong, Wu Zhongting, Zhou Hongmei.. Different response to treatment in the different sites of oral lichen planus: a case report [J]. Inter J Stomatol, 2015, 42(4): 430-431.
[14] Wang Xiaxia, Sun Hongying. Hypoxia-inducible factor-1α and oral lichen planus [J]. Inter J Stomatol, 2015, 42(3): 318-322.
[15] Tang Jinju, Yang Yongjin. Relationship between Helicobacter pylori and recurrent aphthous ulcer [J]. Inter J Stomatol, 2015, 42(1): 89-92.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[2] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[3] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[4] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[5] . [J]. Foreign Med Sci: Stomatol, 1999, 26(06): .
[6] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[7] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[8] . [J]. Foreign Med Sci: Stomatol, 1999, 26(05): .
[9] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .
[10] . [J]. Foreign Med Sci: Stomatol, 1999, 26(04): .